Standout Papers

Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular DegenerationTwelve-W... 2005 2026 2012 2019 518
  1. Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular DegenerationTwelve-Week Results of an Uncontrolled Open-Label Clinical Study (2005)
    Philip J. Rosenfeld, C PULIAFITO et al. Ophthalmology

Immediate Impact

74 standout
Sub-graph 1 of 22

Citing Papers

Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study
2024 Standout
Chemistry, structure and function of approved oligonucleotide therapeutics
2023 Standout
2 intermediate papers

Works of C PULIAFITO being referenced

Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular DegenerationTwelve-Week Results of an Uncontrolled Open-Label Clinical Study
2005 Standout

Author Peers

Author Last Decade Papers Cites
C PULIAFITO 681 547 108 150 3 750
M.F. Escaño 665 504 117 109 11 744
Steven Agemy 669 585 103 50 12 735
Hoseong S. Yang 552 276 16 478 6 802
SE Moss 693 546 23 198 4 921
David Fei 478 423 18 331 7 807
James Warburton 845 641 18 149 5 907
Adam T. Chin 810 762 119 137 14 957
DANIELLE L.L. COSTA 885 401 38 97 11 907
Ahmed Z. Soliman 561 532 20 49 9 651
Maria Swift 677 560 21 151 4 730

All Works

Loading papers...

Rankless by CCL
2026